Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND-9: REGV131-LNP1265 Gene Therapy in Hemophilia B
NCT06379789Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Aug 2034
- Countries
- 9
01
Overview
Phase 2, open-label trial of REGV131 and LNP1265 in hemophilia B (HB) (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment-Emergent Adverse Events up to 2 Years, Severity of Treatment-Emergent Adverse Events up to 2 Years and 9 more. Started Sep 2024; status: recruiting.
02
Drugs
REGV131LNP1265
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT06379789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379789.